NASDAQ$CLOV
Clover Health Investments Corp. · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Clover Health's Q4 2020 financial results were reported, showing revenue growth and increased adoption of the Clover Assistant.
Clover Health reported Q4 2020 financial results, with total revenue reaching $166.2 million and a GAAP MCR of 109.3%. The company experienced a net loss of $81.6 million and an adjusted EBITDA loss of $63.4 million. Membership was 58,056 as of December 31, 2020, and lives under Clover Assistant management surpassed 32,400.
- Total revenue for Q4 2020 reached $166.2 million, compared to $115.3 million in Q4 2019.
- GAAP MCR for Q4 2020 was 109.3%, compared to 99.8% in Q4 2019.
- Net loss for Q4 2020 was $81.6 million, compared to $78.7 million in Q4 2019.
- Adjusted EBITDA loss for Q4 2020 was $63.4 million, compared to $59.1 million in Q4 2019.
Headline financials
Revenue & EPS history
Clover Health · Revenue · Quarterly
$166M
Revenue by segment
Clover Health · $301M total across 1 segment · Q3 2023
- Insurance Revenue$301M+12.4%100.0%
Forward guidance
Clover Health provided full year 2021 guidance, expecting Medicare Advantage membership to be in the range of 68,000 - 70,000 by December 31, 2021. Total revenues are expected to be in the range of $820 - $850 million, and Normalized MCR (Non-GAAP) for Medicare Advantage is expected to be in the range of 89% - 91%.
Tailwinds
- Medicare Advantage membership is expected to be in the range of 68,000 - 70,000 by December 31, 2021, a growth rate of 17% - 21% as compared to year end 2020.
- Total revenues are expected to be in the range of $820 - $850 million, inclusive of a preliminary estimate of approximately $30 to $50 million of revenue generated from Direct Contracting.
- CMS benchmark expenditures under management for Direct Contracting are expected to be in the range of $0.8 billion to $1.1 billion.
- Total Medicare spend under management, which includes revenues from the Medicare Advantage program plus the estimated CMS benchmark for Direct Contracting, is expected to be in the range of $1.6 - $1.9 billion.
- Normalized MCR (Non-GAAP) for Medicare Advantage is expected to be in the range of 89% - 91%.
Headwinds
- MCR for Direct Contracting is expected to be approximately 100%, net of savings targets required by CMS.
- Operating costs are expected to be between $265 and $285 million and reflect the use of a portion of the proceeds from the Merger to make investments in marketing, network expansion and technology to support future growth. These estimates also include extraordinary or nonrecurring costs of approximately $25 million that relate to startup operations of subsidiaries and other one-time legal costs
- Net loss is expected to be in the range of $(210) - $(170) million.
- Adjusted EBITDA loss is expected to be in the range of $(190) - $(150) million.
- Loss per share (basic) in the range of $(0.52) - $(0.42).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-0.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+4.3%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+20.9%
Q1 2024
Best reaction
-15.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.6% | +25.9% | — | |
| Q4 2025 | -3.2% | +0.5% | -18.6% | |
| Q3 2025 | -15.4% | -26.1% | -26.7% | |
| Q1 2025 | +11.9% | +3.6% | -8.8% | |
| Q4 2024 | -4.1% | -7.5% | -13.3% | |
| Q3 2024 | -15.0% | -22.9% | -22.2% | |
| Q2 2024 | +9.6% | +11.4% | +71.6% | |
| Q1 2024 | +20.9% | +13.9% | +52.8% | |
| Q4 2023 | +2.2% | +1.1% | -9.8% | |
| Q3 2023 | -15.2% | -17.2% | -13.0% | |
| Q2 2023 | +10.3% | +19.0% | +4.0% | |
| Q1 2023 | +4.7% | +11.2% | +10.1% | |
| Q4 2022 | -2.2% | -5.2% | -28.3% | |
| Q3 2022 | -5.8% | +11.7% | -13.1% | |
| Q2 2022 | -14.4% | +1.2% | -23.6% | |
| Q1 2022 | -11.9% | -3.0% | -5.2% | |
| Q4 2021 | +20.1% | +33.3% | +72.5% | |
| Q3 2021 | -4.3% | -9.0% | -40.9% | |
| Q2 2021 | +7.1% | +1.0% | +2.1% | |
| Q1 2021 | -6.7% | -7.2% | +73.4% | |
| Q2 2020 | +2.6% | +4.3% | +37.0% | |
| Q4 2020 | -3.8% | -16.6% | -19.6% | |
| Q3 2020 | +0.3% | +0.7% | +9.1% | |
| Q4 2019 | -0.1% | -0.2% | +10.2% | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro